Global GLP-1 Receptor Agonist Market Insights Forecasts to 2032
- The Global GLP-1 Receptor Agonist Market Size was valued at USD 13.4 Billion in 2022.
- The Global GLP-1 Receptor Agonist Market Size is growing at a CAGR of 6.09% from 2022 to 2032.
- The worldwide GLP-1 Receptor Agonist Market Size is expected to reach USD 24.2 Billion by 2032.
- Asia Pacific is expected to grow the fastest during the forecast period.
Get more details on this report -
The Global GLP-1 Receptor Agonist Market Size is expected to reach USD 24.2 billion by 2032, at a CAGR of 6.09% during the forecast period 2022 to 2032.
GLP-1 receptor agonists bind to and activate GLP-1 receptors to promote physiological processes in the body. GLP-1 receptor agonists enhance insulin secretion by interacting with GLP-1 receptors in pancreatic beta cells. As a result, GLP-1 receptor agonists can be utilized to treat diabetes. Inhibiting glucagon production from pancreatic alpha cells in the presence of high blood sugar levels is one of the advantages of employing a GLP-1 receptor agonist for the treatment of type 2 diabetes. Glucagon is a hormone that stimulates the liver to convert glycogen into glucose, hence raising the concentration of glucose in the blood. Furthermore, GLP-1 receptor agonists can enhance pancreatic beta-cell proliferation while decreasing apoptosis or cell death. Furthermore, GLP-1 receptor agonists reduce the emptying of gastric juices, resulting in a slower release of nutrients from food and preventing blood glucose spikes. GLP-1 receptor agonists can also be utilized to treat obesity, liver cirrhosis, cardiovascular disease, and other disorders.
This research report categorizes the global GLP-1 receptor agonist market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global GLP-1 receptor agonist market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global GLP-1 receptor agonist market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global GLP-1 Receptor Agonist Market Report Coverage
|Market Size in 2022:||USD 13.4 Billion|
|Forecast Period 2022-2032 CAGR:||6.09%|
|2032 Value Projection:||USD 24.2 Billion|
|Historical Data for:||2019-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||130|
|Segments covered:||By Drug Class, By Type, By Application, By Route of Administration, By Region, and COVID-19 Impact Analysis|
|Companies Covered:||Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer.Inc, Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., and Boehringer Ingelheim International GmbH And Other Key Venders|
|Pitfalls & Challenges:||COVID-19 has the potential to impact the global market|
Get more details on this report -
Innovative treatments are being developed, which are expected to drive the expansion of the GLP-1 receptor agonist market. Pharmaceutical companies are working on innovative formulations, improved bioavailability, combination treatments, and modes of administration. Also, obesity hurts the heart, kidneys, liver, and mental health. It contributes to a variety of disorders, including type 2 diabetes, cardiovascular disease, hypertension, stroke, and cancer. According to the World Health Organization, over one billion people will be obese by 2022, with 650 million adults, 340 million adolescents, and 39 million children being the most obese. Diabetes and obesity are growing increasingly frequent, and it is vital to manage these chronic diseases. GLP-1 receptor agonists (GLP-1) are a kind of medication used to treat diabetes and obesity. Diabetes and obesity are predicted to drive the global expansion of the GLP-1 receptor agonist market.
Restricted FDA and other regulatory standards for new medication approval are expected to hamper the growth of the glucagon-like peptide 1 (GLP-1) agonists market during the forecast period. However, a lack of appropriate insurance plans may impede the expansion of the glucagon-like peptide 1 (GLP-1) agonists market shortly.
- In 2022, the semaglutide segment is dominating the largest market share over the forecast period.
Based on the drug class, the global GLP-1 receptor agonist market is segmented into semaglutide, dulaglutide, liraglutide, exenatide. Among these segments, the parenteral segment is expected to have significant development potential over the analysis period due to It is a family of medications intended to treat obesity and improve glycemic control in persons with type 2 diabetes mellitus. It is also recommended for persons with type 2 diabetes to lower the risk of serious cardiovascular events. Along with this, the rising incidence of diabetes and obesity enhances demand for semaglutide, propelling the market forward.
- In 2022, the trulicity segment is influencing the market with the largest market share during the forecast period.
On the basis of type, the global GLP-1 receptor agonist market is bifurcated into victoza, ozempic, saxenda, trulicity, bydureon. Among these segments, the victoza segment is dominating the market with the largest revenue share during the forecast period. This is owing to their ease of use, which allows for self-administration utilizing a pre-filled pen and a once-weekly dosing regimen. Furthermore, the growing need for more practical and user-friendly treatment options, particularly among elderly patients, is likely to fuel revenue growth in this sector.
- In 2022, the type 2 diabetes segment is dominating the largest market share over the forecast period.
Based on the application, the global GLP-1 receptor agonist market is segmented into different categories such as type 2 diabetes, obesity, and others. Among these segments, the type 2 diabetes segment is dominating the market during the forecast period due to when blood glucose levels are high, the GLP-1 receptor agonist plays a key function in boosting insulin release and inhibiting glucagon production. They aid in the treatment of type 2 diabetes and encourage weight reduction. Factors such as the rising prevalence of type 2 diabetes, higher treatment demand, and increased prescriptions for GLP-1 receptor agonist medications are all contributing to the segment's expansion.
- In 2022, the parenteral segment is dominating the market with the largest market share during the forecast period.
Based on the route of administration, the global GLP-1 receptor agonist market is segmented into parenteral and oral. Among these segments, the parenteral segment is expected to have significant development potential over the analysis period due to the benefits provided, such as the fast onset of action, improved bioavailability, simple absorption of active forms of drugs, and zero likelihood of interference. Many GLP-1 receptor agonist medicines are delivered by parenteral methods, such as Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), and Exenatide (Bydureon, Byetta).
Regional Segment Analysis of the GLP-1 Receptor Agonist Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America influenced the market with the largest market share over the forecast period
Get more details on this report -
North America is influencing significant market growth during the forecast period due to the region's high prevalence of chronic illnesses such as diabetes and obesity, rising R&D investments for creating novel pharmaceuticals for treating diabetes and obesity, the presence of significant companies, and the well-developed healthcare infrastructure.
Asia Pacific is expected to experience high revenue market growth during the forecast period due to Factors contributing to its rapid development including rising rates of metabolic disorders such as diabetes and obesity in China and Australia, a large number of undiscovered prospects, and increased R&D spending.
The report offers the appropriate analysis of the key organizations/companies involved within the global GLP-1 receptor agonist market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Eli Lilly and Company
- Novo-Nordisk A/S
- Amgen, Inc.
- Innovent Biologics, Inc.
- PegBio Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In March 2023, the NHS approved Wegovy, a weight reduction injectable that mimics the hormone glucagon-like peptide-1 (GLP-1) and inhibits hunger. Wegovy, also known as semaglutide, will now be available to thousands of obese individuals in England through the NHS.
- In November 2021, Novo Nordisk A/S and Dicerna Pharmaceuticals, Inc. established a collaboration to develop and market Ribonucleic Acid (RNA) interference medicines for the treatment of liver-related cardiometabolic illnesses such as Non-Alcoholic Steatohepatitis (NASH) and type 2 diabetes.
This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global GLP-1 Receptor Agonist Market based on the below-mentioned segments:
Global GLP-1 Receptor Agonist Market, By Drug Class
Global GLP-1 Receptor Agonist Market, By Type
Global GLP-1 Receptor Agonist Market, By Application
- Type 2 Diabetes
Global GLP-1 Receptor Agonist Market, By Route of Administration
GLP-1 Receptor Agonist Market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
Need help to buy this report?